Laboratory Medicine ›› 2017, Vol. 32 ›› Issue (7): 590-596.DOI: 10.3969/j.issn.1673-8640.2017.07.008
• Orginal Article • Previous Articles Next Articles
LIN Jiafei1, WU Jiayi2, CAI Gang1, WU Beiying1, LIN Lin1
Received:
2017-03-01
Online:
2017-08-08
Published:
2017-08-09
CLC Number:
LIN Jiafei, WU Jiayi, CAI Gang, WU Beiying, LIN Lin. Analysis of 21-gene recurrence score in 459 patients with breast cancer[J]. Laboratory Medicine, 2017, 32(7): 590-596.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2017.07.008
临床病理特征 | 例数 | 百分比(%) | 临床病理特征 | 例数 | 百分比(%) | 临床病理特征 | 例数 | 百分比(%) |
---|---|---|---|---|---|---|---|---|
年龄(岁) | 病理类型 | 分子分型 | ||||||
≤50 | 149 | 32.5 | 浸润性导管癌 | 416 | 90.6 | Luminal A | 139 | 30.3 |
>50 | 310 | 67.5 | 其他浸润性癌 | 43 | 9.4 | Luminal B | 317 | 69.1 |
肿块大小(cm) | 组织学分级 | 未知 | 3 | 0.6 | ||||
≤2 | 289 | 63.0 | Ⅰ级 | 51 | 11.1 | PR | ||
>2 | 170 | 37.0 | Ⅱ级 | 260 | 56.7 | 阴性 | 80 | 17.4 |
肿块位置 | Ⅲ级 | 105 | 22.9 | 阳性 | 379 | 82.6 | ||
内上 | 112 | 24.4 | 未知 | 43 | 9.3 | Ki67(%) | ||
内下 | 30 | 6.5 | 临床分期 | <14 | 229 | 49.9 | ||
外上 | 189 | 41.2 | Ⅰ期 | 257 | 56.0 | ≥14 | 230 | 50.1 |
外下 | 49 | 10.7 | Ⅱ期 | 186 | 40.5 | 淋巴结状态 | ||
乳头乳晕 | 23 | 5.0 | Ⅲ期 | 4 | 0.9 | 阴性 | 422 | 91.9 |
未知 | 56 | 12.2 | 未知 | 12 | 2.6 | 阳性 | 37 | 8.1 |
临床病理特征 | 例数 | 百分比(%) | 临床病理特征 | 例数 | 百分比(%) | 临床病理特征 | 例数 | 百分比(%) |
---|---|---|---|---|---|---|---|---|
年龄(岁) | 病理类型 | 分子分型 | ||||||
≤50 | 149 | 32.5 | 浸润性导管癌 | 416 | 90.6 | Luminal A | 139 | 30.3 |
>50 | 310 | 67.5 | 其他浸润性癌 | 43 | 9.4 | Luminal B | 317 | 69.1 |
肿块大小(cm) | 组织学分级 | 未知 | 3 | 0.6 | ||||
≤2 | 289 | 63.0 | Ⅰ级 | 51 | 11.1 | PR | ||
>2 | 170 | 37.0 | Ⅱ级 | 260 | 56.7 | 阴性 | 80 | 17.4 |
肿块位置 | Ⅲ级 | 105 | 22.9 | 阳性 | 379 | 82.6 | ||
内上 | 112 | 24.4 | 未知 | 43 | 9.3 | Ki67(%) | ||
内下 | 30 | 6.5 | 临床分期 | <14 | 229 | 49.9 | ||
外上 | 189 | 41.2 | Ⅰ期 | 257 | 56.0 | ≥14 | 230 | 50.1 |
外下 | 49 | 10.7 | Ⅱ期 | 186 | 40.5 | 淋巴结状态 | ||
乳头乳晕 | 23 | 5.0 | Ⅲ期 | 4 | 0.9 | 阴性 | 422 | 91.9 |
未知 | 56 | 12.2 | 未知 | 12 | 2.6 | 阳性 | 37 | 8.1 |
组别 | 年龄(岁)(459例) | 肿块大小(cm)(459例) | 肿块位置(403例) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
≤50 | >50 | ≤2 | >2 | 内上 | 内下 | 外上 | 外下 | 乳头乳晕 | ||||||||||
低危组 | 31 | 86 | 84 | 33 | 33 | 3 | 52 | 12 | 2 | |||||||||
中危组 | 93 | 161 | 155 | 99 | 58 | 21 | 101 | 27 | 16 | |||||||||
高危组 | 25 | 63 | 50 | 38 | 21 | 6 | 36 | 10 | 5 | |||||||||
χ2值 | 4.556 | 5.748 | 8.944 | |||||||||||||||
P值 | 0.102 | 0.056 | 0.347 | |||||||||||||||
组别 | 病理类型(459例) | 组织学分级(416例) | 临床分期(447例) | |||||||||||||||
浸润性导管癌 | 其他浸润性癌 | Ⅰ级 | Ⅱ级 | Ⅲ级 | Ⅰ期 | Ⅱ期 | Ⅲ期 | |||||||||||
低危组 | 105 | 12 | 20 | 72 | 13 | 74 | 38 | 2 | ||||||||||
中危组 | 230 | 24 | 27 | 152 | 51 | 136 | 110 | 2 | ||||||||||
高危组 | 81 | 7 | 4 | 36 | 41 | 47 | 38 | 0 | ||||||||||
χ2值 | 0.853 | 41.259 | 5.712 | |||||||||||||||
P值 | 0.853 | <0.001 | 0.222 | |||||||||||||||
组别 | 分子分型(456例) | PR(459例) | Ki67(%)(459例) | 淋巴结状态(459例) | ||||||||||||||
Luminal A | Luminal B | 阴性 | 阳性 | <14 | ≥14 | 未转移 | 转移 | |||||||||||
低危组 | 51 | 65 | 8 | 109 | 64 | 53 | 96 | 21 | ||||||||||
中危组 | 82 | 170 | 41 | 213 | 137 | 117 | 209 | 45 | ||||||||||
高危组 | 6 | 82 | 31 | 57 | 28 | 60 | 73 | 15 | ||||||||||
χ2值 | 33.710 | 28.783 | 14.243 | 0.030 | ||||||||||||||
P值 | <0.001 | <0.001 | 0.001 | 0.985 |
组别 | 年龄(岁)(459例) | 肿块大小(cm)(459例) | 肿块位置(403例) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
≤50 | >50 | ≤2 | >2 | 内上 | 内下 | 外上 | 外下 | 乳头乳晕 | ||||||||||
低危组 | 31 | 86 | 84 | 33 | 33 | 3 | 52 | 12 | 2 | |||||||||
中危组 | 93 | 161 | 155 | 99 | 58 | 21 | 101 | 27 | 16 | |||||||||
高危组 | 25 | 63 | 50 | 38 | 21 | 6 | 36 | 10 | 5 | |||||||||
χ2值 | 4.556 | 5.748 | 8.944 | |||||||||||||||
P值 | 0.102 | 0.056 | 0.347 | |||||||||||||||
组别 | 病理类型(459例) | 组织学分级(416例) | 临床分期(447例) | |||||||||||||||
浸润性导管癌 | 其他浸润性癌 | Ⅰ级 | Ⅱ级 | Ⅲ级 | Ⅰ期 | Ⅱ期 | Ⅲ期 | |||||||||||
低危组 | 105 | 12 | 20 | 72 | 13 | 74 | 38 | 2 | ||||||||||
中危组 | 230 | 24 | 27 | 152 | 51 | 136 | 110 | 2 | ||||||||||
高危组 | 81 | 7 | 4 | 36 | 41 | 47 | 38 | 0 | ||||||||||
χ2值 | 0.853 | 41.259 | 5.712 | |||||||||||||||
P值 | 0.853 | <0.001 | 0.222 | |||||||||||||||
组别 | 分子分型(456例) | PR(459例) | Ki67(%)(459例) | 淋巴结状态(459例) | ||||||||||||||
Luminal A | Luminal B | 阴性 | 阳性 | <14 | ≥14 | 未转移 | 转移 | |||||||||||
低危组 | 51 | 65 | 8 | 109 | 64 | 53 | 96 | 21 | ||||||||||
中危组 | 82 | 170 | 41 | 213 | 137 | 117 | 209 | 45 | ||||||||||
高危组 | 6 | 82 | 31 | 57 | 28 | 60 | 73 | 15 | ||||||||||
χ2值 | 33.710 | 28.783 | 14.243 | 0.030 | ||||||||||||||
P值 | <0.001 | <0.001 | 0.001 | 0.985 |
组别 | 年龄(岁)(422例) | 肿块大小(cm)(422例) | 肿块位置(367例) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
≤50 | >50 | ≤2 | >2 | 内上 | 内下 | 外上 | 外下 | 乳头乳晕 | |||||||||
低危组 | 28 | 79 | 78 | 29 | 32 | 3 | 44 | 12 | 2 | ||||||||
中危组 | 90 | 144 | 148 | 86 | 54 | 20 | 91 | 24 | 14 | ||||||||
高危组 | 24 | 57 | 49 | 32 | 17 | 6 | 35 | 9 | 4 | ||||||||
χ2值 | 5.695 | 3.976 | 8.464 | ||||||||||||||
P值 | 0.058 | 0.137 | 0.390 | ||||||||||||||
组别 | 病理类型(422例) | 组织学分级(382例) | 临床分期(411例) | ||||||||||||||
浸润性导管癌 | 其他浸润性癌 | Ⅰ级 | Ⅱ级 | Ⅲ级 | Ⅰ期 | Ⅱ期 | Ⅲ期 | ||||||||||
低危组 | 96 | 11 | 20 | 65 | 11 | 74 | 30 | 0 | |||||||||
中危组 | 211 | 23 | 27 | 138 | 46 | 136 | 90 | 0 | |||||||||
高危组 | 75 | 6 | 4 | 33 | 38 | 47 | 31 | 0 | |||||||||
χ2值 | 0.519 | 40.329 | 4.438 | ||||||||||||||
P值 | 0.722 | <0.001 | 0.109 | ||||||||||||||
组别 | 分子分型(420例) | PR(422例) | Ki67(%)(422例) | ||||||||||||||
Luminal A | Luminal B | 阴性 | 阳性 | <14 | ≥14 | ||||||||||||
低危组 | 47 | 59 | 8 | 99 | 60 | 47 | |||||||||||
中危组 | 75 | 158 | 40 | 194 | 126 | 108 | |||||||||||
高危组 | 6 | 75 | 30 | 51 | 27 | 54 | |||||||||||
χ2值 | 30.282 | 27.409 | 11.927 | ||||||||||||||
P值 | <0.001 | <0.001 | 0.003 |
组别 | 年龄(岁)(422例) | 肿块大小(cm)(422例) | 肿块位置(367例) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
≤50 | >50 | ≤2 | >2 | 内上 | 内下 | 外上 | 外下 | 乳头乳晕 | |||||||||
低危组 | 28 | 79 | 78 | 29 | 32 | 3 | 44 | 12 | 2 | ||||||||
中危组 | 90 | 144 | 148 | 86 | 54 | 20 | 91 | 24 | 14 | ||||||||
高危组 | 24 | 57 | 49 | 32 | 17 | 6 | 35 | 9 | 4 | ||||||||
χ2值 | 5.695 | 3.976 | 8.464 | ||||||||||||||
P值 | 0.058 | 0.137 | 0.390 | ||||||||||||||
组别 | 病理类型(422例) | 组织学分级(382例) | 临床分期(411例) | ||||||||||||||
浸润性导管癌 | 其他浸润性癌 | Ⅰ级 | Ⅱ级 | Ⅲ级 | Ⅰ期 | Ⅱ期 | Ⅲ期 | ||||||||||
低危组 | 96 | 11 | 20 | 65 | 11 | 74 | 30 | 0 | |||||||||
中危组 | 211 | 23 | 27 | 138 | 46 | 136 | 90 | 0 | |||||||||
高危组 | 75 | 6 | 4 | 33 | 38 | 47 | 31 | 0 | |||||||||
χ2值 | 0.519 | 40.329 | 4.438 | ||||||||||||||
P值 | 0.722 | <0.001 | 0.109 | ||||||||||||||
组别 | 分子分型(420例) | PR(422例) | Ki67(%)(422例) | ||||||||||||||
Luminal A | Luminal B | 阴性 | 阳性 | <14 | ≥14 | ||||||||||||
低危组 | 47 | 59 | 8 | 99 | 60 | 47 | |||||||||||
中危组 | 75 | 158 | 40 | 194 | 126 | 108 | |||||||||||
高危组 | 6 | 75 | 30 | 51 | 27 | 54 | |||||||||||
χ2值 | 30.282 | 27.409 | 11.927 | ||||||||||||||
P值 | <0.001 | <0.001 | 0.003 |
影响因子 | 中危组相对于低危组 | 高危组相对于低危组 | |||
---|---|---|---|---|---|
OR 值(95% CI) | P值 | OR值(95% CI) | P值 | ||
总体样本 | |||||
年龄(岁) | |||||
≤50 | 2.540(1.286~4.646) | 0.002 | 2.142(0.947~4.847) | 0.067 | |
>50 | 1 | 1 | |||
分子分型 | |||||
Luminal A | 0.398(0.163~0.974) | 0.044 | 0.164(0.045~0.600) | 0.006 | |
Luminal B | 1 | 1 | |||
组织学分级 | |||||
Ⅰ级 | 0.158(0.049~0.507) | 0.002 | 0.033(0.006~0.182) | <0.001 | |
Ⅱ级 | 0.322(0.134~0.775) | 0.011 | 0.118(0.044~0.314) | <0.001 | |
Ⅲ级 | 1 | 1 | |||
PR | |||||
阴性 | 4.122(1.286~13.211) | 0.017 | 9.478(2.719~33.030) | <0.001 | |
阳性 | 1 | 1 | |||
淋巴结阴性 | |||||
年龄(岁) | |||||
≤50 | 2.626(1.456~4.736) | 0.001 | 2.069(0.929~4.610) | 0.075 | |
>50 | 1 | 1 | |||
分子分型 | |||||
Luminal A | 0.440(0.189~1.022) | 0.056 | 0.150(0.043~0.523) | 0.003 | |
Luminal B | 1 | 1 | |||
组织学分级 | |||||
Ⅰ级 | 0.234(0.077~0.710) | 0.010 | 0.054(0.012~0.254) | <0.001 | |
Ⅱ级 | 0.400(0.185~0.970) | 0.043 | 0.125(0.047~0.333) | <0.001 | |
Ⅲ级 | 1 | 1 | |||
PR | |||||
阴性 | 4.991(1.581~15.761) | 0.006 | 9.203(2.678~31.627) | <0.001 | |
阳性 | 1 | 1 |
影响因子 | 中危组相对于低危组 | 高危组相对于低危组 | |||
---|---|---|---|---|---|
OR 值(95% CI) | P值 | OR值(95% CI) | P值 | ||
总体样本 | |||||
年龄(岁) | |||||
≤50 | 2.540(1.286~4.646) | 0.002 | 2.142(0.947~4.847) | 0.067 | |
>50 | 1 | 1 | |||
分子分型 | |||||
Luminal A | 0.398(0.163~0.974) | 0.044 | 0.164(0.045~0.600) | 0.006 | |
Luminal B | 1 | 1 | |||
组织学分级 | |||||
Ⅰ级 | 0.158(0.049~0.507) | 0.002 | 0.033(0.006~0.182) | <0.001 | |
Ⅱ级 | 0.322(0.134~0.775) | 0.011 | 0.118(0.044~0.314) | <0.001 | |
Ⅲ级 | 1 | 1 | |||
PR | |||||
阴性 | 4.122(1.286~13.211) | 0.017 | 9.478(2.719~33.030) | <0.001 | |
阳性 | 1 | 1 | |||
淋巴结阴性 | |||||
年龄(岁) | |||||
≤50 | 2.626(1.456~4.736) | 0.001 | 2.069(0.929~4.610) | 0.075 | |
>50 | 1 | 1 | |||
分子分型 | |||||
Luminal A | 0.440(0.189~1.022) | 0.056 | 0.150(0.043~0.523) | 0.003 | |
Luminal B | 1 | 1 | |||
组织学分级 | |||||
Ⅰ级 | 0.234(0.077~0.710) | 0.010 | 0.054(0.012~0.254) | <0.001 | |
Ⅱ级 | 0.400(0.185~0.970) | 0.043 | 0.125(0.047~0.333) | <0.001 | |
Ⅲ级 | 1 | 1 | |||
PR | |||||
阴性 | 4.991(1.581~15.761) | 0.006 | 9.203(2.678~31.627) | <0.001 | |
阳性 | 1 | 1 |
组别 | 总体 | 淋巴结阴性 | 淋巴结阳性 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
未化疗 | 化疗 | 合计 | 未化疗 | 化疗 | 合计 | 未化疗 | 化疗 | 合计 | |||
低危组 | 97(82.9) | 20(17.1) | 117(100.0) | 94(87.9) | 13(12.1) | 107(100.0) | 3(30.0) | 7(70.0) | 10(100.0) | ||
中危组 | 103(40.6) | 151(59.4) | 254(100.0) | 100(42.7) | 134(57.3) | 234(100.0) | 3(15.0) | 17(85.0) | 20(100.0) | ||
高危组 | 8(9.1) | 80(90.9) | 88(100.0) | 8(9.9) | 73(90.1) | 81(100.0) | 0(0.0) | 7(100.0) | 7(100.0) | ||
χ2值 | 117.865 | 115.642 | 2.775 | ||||||||
P值 | <0.001 | <0.001 | 0.250 |
组别 | 总体 | 淋巴结阴性 | 淋巴结阳性 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
未化疗 | 化疗 | 合计 | 未化疗 | 化疗 | 合计 | 未化疗 | 化疗 | 合计 | |||
低危组 | 97(82.9) | 20(17.1) | 117(100.0) | 94(87.9) | 13(12.1) | 107(100.0) | 3(30.0) | 7(70.0) | 10(100.0) | ||
中危组 | 103(40.6) | 151(59.4) | 254(100.0) | 100(42.7) | 134(57.3) | 234(100.0) | 3(15.0) | 17(85.0) | 20(100.0) | ||
高危组 | 8(9.1) | 80(90.9) | 88(100.0) | 8(9.9) | 73(90.1) | 81(100.0) | 0(0.0) | 7(100.0) | 7(100.0) | ||
χ2值 | 117.865 | 115.642 | 2.775 | ||||||||
P值 | <0.001 | <0.001 | 0.250 |
[1] | MAMOUNAS E P,TANG G,FISHER B,et al.Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20[J]. J Clin Oncol,2010,28(10): 1677-1683. |
[2] | PAIK S,SHAK S,TANG G,et al.A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer[J]. N Engl J Med,2004,351(27): 2817-2826. |
[3] | PAIK S,TANG G,SHAK S,et al.Gene expression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer[J]. J Clin Oncol,2006,24(23): 3726-3734. |
[4] | LUND M J,MOSUNJAC M,DAVIS K M,et al.21-Gene recurrence scores: racial differences in testing,scores,treatment,and outcome[J]. Cancer,2012,118(3): 788-796. |
[5] | SPARANO J A,GRAY R J,MAKOWER D F,et al.Prospective validation of a 21-gene expression assay in breast cancer[J]. N Engl J Med,2015,373(21): 2005-2014. |
[6] | TANG G,CUZICK J,COSTANTINO J P,et al.Risk of recurrence and chemotherapy benefit for patients with node-negative,estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors[J]. J Clin Oncol,2011,29(33): 4365-4372. |
[7] | ZUJEWSKI J A,KAMIN L.Trial assessing individualized options for treatment for breast cancer: the TAILORx trial[J]. Future Oncol,2008,4(5): 603-610. |
[1] | WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817. |
[2] | CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578. |
[3] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429. |
[4] | LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239. |
[5] | LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147. |
[6] | GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206,miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068. |
[7] | WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820. |
[8] | YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517. |
[9] | YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348. |
[10] | ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40. |
[11] | LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718. |
[12] | YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329. |
[13] | LIU Xiufen, AO Hongfeng, AO Jinping. Expression of programmed cell death 5 in breast cancer and its clinical value [J]. Laboratory Medicine, 2021, 36(11): 1151-1158. |
[14] | JIN Shu, ZHU Qi, ZHU Yuan, YUAN Ya, CAI Xiaoyao, ZHANG Ji, YAN Peiyi. Methylation level and mRNA expression of CpG island of HER2 gene in breast cancer and its adjacent tissues [J]. Laboratory Medicine, 2020, 35(5): 481-486. |
[15] | ZHANG Xiaoying. Relationship between the changes of TK1 and ID-1 levels and curative effect in cervical cancer patients before and after neoadjuvant chemotherapy [J]. Laboratory Medicine, 2020, 35(2): 108-111. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||